

Group Art Unit: 1642

Examiner: Christopher H. YAEN

Applicant(s): McCormick et al.

Serial No.: 09/539,382

Filed: 03/31/2000

Title: Self Antigen Vaccines for Treating B-

Cell Lymphomas and Other Cancers

Attorney Docket No.: 42204

MS RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This Information Disclosure Statement is being submitted under 37 CFR 1.97(b) along with a Request for Continued Examination (RCE) under 37 CFR 1.114.

Applicant submit herewith Form PTO 1449-Information Disclosure Citation together with copies, of patents, publications or other information of which applicant(s) are aware, which applicant(s) believe(s) may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56.

The references cited listed on Form PTO 1449 were recently cited in a Search Report in a related PCT application. A copy of the Search Report also accompanies this statement.

The relevance of the attached references is that this is the closest art of which Applicant is aware. Applicant submits that the above references taken alone or in combination neither

U.S. Patent Application No. 09/539,382

Attorney Docket No.: 42204

anticipate nor render obvious the present invention. Consideration of the foregoing in relation to this application is respectfully requested.

It is requested that the information disclosed herein be made of record in this application.

Date: g March 2005

Respectfully submitted,

Thomas Gallegos, Reg. No. 32,692

Sr. Director, Intellectual Property

Large Scale Biology Corporation 3333 Vaca Valley Parkway, Suite 1000

Vacaville, CA 95688 Tel.: (707) 469-2307 Fax: (707) 446-3917

I hereby certify that this Correspondence is being deposited with the United States Postal service with sufficient postage for first class mail in an envelope address to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or the correspondence is being facsimile transmitted to the USPTO, on the date indicated below.

Date of Deposit:

Thomas Gallegos, Reg. No. 32,692

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 po persons are required to respond to a collection of information unless it displays a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO 09/539,382 Application Number INFORMATION DISCLOSURE 03/31/2000 Filing Date STATEMENT BY APPLICANT First Named Inventor McCormick et al. Art Unit (Use as many sheets as necessary) 1642 **Examiner Name** Christopher H. YAEN 42204 Attorney Docket Number Sheet

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number  Number - Kind Code <sup>2 (# known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		US-6,403,371	06/11/2002	CONRAD et al.		

Cite Io.1	Foreign Patent Document  Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
					<u> </u>
					-
					ļ
			ite MM DD-VVVV	ite MM_DD_VVVV Applicant of Cited Document	ite AMA DD YYYY Applicant of Cited Document Where Relevant Passages

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>			
		SHU, et al., "Secretion of a single-gene-encoded immunoglobulin from myeloma cells", Proc. Natl. Acad. Sci. USA (1993) 90:7995-7999				

Examiner	`	Date	
Signature		Considered	
	1		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.